BR112023016682A2 - Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista - Google Patents

Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista

Info

Publication number
BR112023016682A2
BR112023016682A2 BR112023016682A BR112023016682A BR112023016682A2 BR 112023016682 A2 BR112023016682 A2 BR 112023016682A2 BR 112023016682 A BR112023016682 A BR 112023016682A BR 112023016682 A BR112023016682 A BR 112023016682A BR 112023016682 A2 BR112023016682 A2 BR 112023016682A2
Authority
BR
Brazil
Prior art keywords
obicetrapib
ezetimibe
hyperlipidemia
statin
mixed dyslipidemia
Prior art date
Application number
BR112023016682A
Other languages
English (en)
Portuguese (pt)
Inventor
Jacob Pieter Kastelein Johannes
Marc Ditmarsch
Harvey Davidson Michael
Original Assignee
Newamsterdam Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newamsterdam Pharma B V filed Critical Newamsterdam Pharma B V
Publication of BR112023016682A2 publication Critical patent/BR112023016682A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023016682A 2021-02-18 2022-02-18 Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista BR112023016682A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2021050109 2021-02-18
PCT/NL2022/050083 WO2022177428A1 (en) 2021-02-18 2022-02-18 Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia

Publications (1)

Publication Number Publication Date
BR112023016682A2 true BR112023016682A2 (pt) 2023-11-14

Family

ID=74844966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016682A BR112023016682A2 (pt) 2021-02-18 2022-02-18 Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista

Country Status (11)

Country Link
US (1) US20240189311A1 (https=)
EP (1) EP4294387A1 (https=)
JP (1) JP2024507810A (https=)
KR (1) KR20230159380A (https=)
CN (1) CN117042770A (https=)
AU (1) AU2022223224A1 (https=)
BR (1) BR112023016682A2 (https=)
CA (1) CA3210033A1 (https=)
IL (1) IL304544A (https=)
MX (1) MX2023009613A (https=)
WO (1) WO2022177428A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024165395A1 (en) * 2023-02-07 2024-08-15 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025146445A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib and ezetimibe
WO2025146262A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146446A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib
WO2025147235A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MX369471B (es) * 2014-02-05 2019-11-08 Dezima Pharma B V Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares.
WO2017023166A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor
US12006305B2 (en) * 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
JP2025527686A (ja) * 2022-08-22 2025-08-22 ニューアムステルダム・ファルマ・ベー・フェー オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物

Also Published As

Publication number Publication date
JP2024507810A (ja) 2024-02-21
AU2022223224A1 (en) 2023-08-24
CN117042770A (zh) 2023-11-10
IL304544A (en) 2023-09-01
MX2023009613A (es) 2023-11-09
WO2022177428A1 (en) 2022-08-25
EP4294387A1 (en) 2023-12-27
KR20230159380A (ko) 2023-11-21
US20240189311A1 (en) 2024-06-13
CA3210033A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
BR112023016682A2 (pt) Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista
BR112022012637A2 (pt) Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1
BR112022013746A2 (pt) Formulação aquosa de cagrilintida, formulação aquosa de semaglutida, dispositivo médico, e, combinação de dose fixa
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
BR112021025306A2 (pt) Medicamento e seu uso para o tratamento de infecções bacterianas envolvendo biofilme
BR112022015800A2 (pt) Tratamento de colangite biliar primária com elafibranor
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
MX2025004819A (es) Nuevos derivados dioxano
BR112019006174A2 (pt) proteina terapêutica
BR112022009510A2 (pt) Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição
BR112022004851A2 (pt) Uso de inibidores de dkk-1 para tratar câncer
BRPI0804070A2 (pt) usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112021014911A2 (pt) Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer
JOP20250174A1 (ar) بروتينات اندماج il-12 fc
MX2025004758A (es) Compuestos y su uso para el tratamiento de hemoglobinopatias
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica